Glimpses of ICD 10 CM Revised Codes - 2022

Changes Codes Description

Revise from: G7120 Congenital myopathy, unspecified

Revise to: G7120 Congenital myopathy, unspecified

Revise from: M3500 Sicca syndrome, unspecified

Revise to: M3500 Sjogren syndrome, unspecified

Revise from: M3501 Sicca  syndrome with keratoconjunctivitis

Revise to: M3501 Sjogren syndrome with keratoconjunctivitis

Revise from: M3502 Sicca  syndrome with lung involvement

Revise to: M3502 Sjogren syndrome with lung involvement

Revise from: M3503 Sicca syndrome with myopathy

Revise to: M3503 Sjogren syndrome with myopathy

Revise from: M3504 Sicca syndrome with tubulo-interstitial nephropathy

Revise to: M3504 Sjogren syndrome with tubulo-interstitial nephropathy

Revise from: M3509 Sicca  syndrome with other organ involvement

Revise to: M3509 Sjogren syndrome with other organ involvement

Revise from: T63611A Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter

Revise to: T63611A Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), initial encounter

Revise from: T63611D Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), subsequent encounter

Revise to: T63611D Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), subsequent encounter

Revise from: T63611S Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), sequela

Revise to: T63611S Toxic effect of contact with Portuguese Man-o-war, accidental (unintentional), sequela

Revise from: T63612A Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter

Revise to: T63612A Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, initial encounter

Revise from: T63612D Toxic effect of contact with Portugese Man-o-war, intentional self-harm, subsequent encounter

Revise to: T63612D Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, subsequent encounter

Revise from: T63612S Toxic effect of contact with Portugese Man-o-war, intentional self-harm, sequela

Revise to: T63612S Toxic effect of contact with Portuguese Man-o-war, intentional self-harm, sequela

Revise from: T63613A Toxic effect of contact with Portugese Man-o-war, assault, initial encounter

Revise to: T63613A Toxic effect of contact with Portuguese Man-o-war, assault, initial encounter

Revise from: T63613D Toxic effect of contact with Portugese Man-o-war, assault, subsequent encounter

Revise to: T63613D Toxic effect of contact with Portuguese Man-o-war, assault, subsequent encounter

Revise from: T63613S Toxic effect of contact with Portugese Man-o-war, assault, sequela

Revise to: T63613S Toxic effect of contact with Portuguese Man-o-war, assault, sequela

Revise from: T63614A Toxic effect of contact with Portugese Man-o-war, undetermined, initial encounter

Revise to: T63614A Toxic effect of contact with Portuguese Man-o-war, undetermined, initial encounter

Revise from: T63614D Toxic effect of contact with Portugese Man-o-war, undetermined, subsequent encounter

Revise to: T63614D Toxic effect of contact with Portuguese Man-o-war, undetermined, subsequent encounter

Revise from: T63614S Toxic effect of contact with Portugese Man-o-war, undetermined, sequela

Revise to: T63614S Toxic effect of contact with Portuguese Man-o-war, undetermined, sequela

Revise from: Z9225 Personal history of immunosupression therapy

Revise to: Z9225 Personal history of immunosuppression therapy

Return to view New Codes

Check Deleted Codes

Glimpses of ICD 10 CM Deleted Codes - 2022

Deleted Codes Description

D552  Anemia due to disorders of glycolytic enzymes

F78  Other intellectual disabilities

G92 Toxic encephalopathy

K228 Other specified diseases of esophagus

M311 Thrombotic microangiopathy

M545 Low back pain

P09  Abnormal findings on neonatal screening

R05  Cough

R358  Other polyuria

R633  Feeding difficulties

T407X1A  Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter

T407X1D  Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter

T407X1S  Poisoning by cannabis (derivatives), accidental (unintentional), sequela

T407X2A  Poisoning by cannabis (derivatives), intentional self-harm, initial encounter

T407X2D  Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter

T407X2S  Poisoning by cannabis (derivatives), intentional self-harm, sequela

T407X3A  Poisoning by cannabis (derivatives), assault, initial encounter

T407X3D  Poisoning by cannabis (derivatives), assault, subsequent encounter

T407X3S  Poisoning by cannabis (derivatives), assault, sequela

T407X4A  Poisoning by cannabis (derivatives), undetermined, initial encounter

T407X4D  Poisoning by cannabis (derivatives), undetermined, subsequent encounter

T407X4S   Poisoning by cannabis (derivatives), undetermined, sequela

T407X5A  Adverse effect of cannabis (derivatives), initial encounter

T407X5D  Adverse effect of cannabis (derivatives), subsequent encounter

T407X5S  Adverse effect of cannabis (derivatives), sequela

T407X6A  Underdosing of cannabis (derivatives), initial encounter

T407X6D Underdosing of cannabis (derivatives), subsequent encounter

T407X6S  Underdosing of cannabis (derivatives), sequela

Z590  Homelessness

Z594  Lack of adequate food and safe drinking water

Z598  Other problems related to housing and economic circumstances

Z915  Personal history of self-harm

Click here to view ICD 10 CM Revised Codes - 2022

Glimpses of ICD 10 CM Codes - 2022

Just see below for the number of codes that are added, deleted, and revised in 2022

Total numbers of codes in  2021  - 72621 codes

Total numbers of codes in  2022  - 72748 codes

ICD 10 CM Updates for 2022

Total changes - 211

159 additions

32 deletions

20 revisions

Click here to check the list of New ICD 10 CM Codes

Glimpses of ICD 10 CM New Codes - 2022

 ICD 10 CM New Code Description

A7982 Anaplasmosis [A. phagocytophilum]

C563 Malignant neoplasm of bilateral ovaries

C7963 Secondary malignant neoplasm of bilateral ovaries

C847A Anaplastic large cell lymphoma, ALK-negative, breast

D5521 Anemia due to pyruvate kinase deficiency

D5529 Anemia due to other disorders of glycolytic enzymes

D75838 Other thrombocytosis

D75839 Thrombocytosis, unspecified

D8944 Hereditary alpha tryptasemia

E75244 Niemann-Pick disease type A/B

F32A Depression, unspecified

F78A1 SYNGAP1-related intellectual disability

F78A9 Other genetic related intellectual disability

G0482 Acute flaccid myelitis

G4486 Cervicogenic headache

G9200 Immune effector cell-associated neurotoxicity syndrome, grade unspecified

G9201 Immune effector cell-associated neurotoxicity syndrome, grade 1

G9202 Immune effector cell-associated neurotoxicity syndrome, grade 2

G9203 Immune effector cell-associated neurotoxicity syndrome, grade 3

G9204 Immune effector cell-associated neurotoxicity syndrome, grade 4

G9205 Immune effector cell-associated neurotoxicity syndrome, grade 5

G928 Other toxic encephalopathy

G929 Unspecified toxic encephalopathy

I5A Non-ischemic myocardial injury (non-traumatic)

K2281 Esophageal polyp

K2282 Esophagogastric junction polyp

K2289 Other specified disease of esophagus

K31A0 Gastric intestinal metaplasia, unspecified

K31A11 Gastric intestinal metaplasia without dysplasia, involving the antrum

K31A12 Gastric intestinal metaplasia without dysplasia, involving the body (corpus)

K31A13 Gastric intestinal metaplasia without dysplasia, involving the fundus

K31A14 Gastric intestinal metaplasia without dysplasia, involving the cardia

K31A15 Gastric intestinal metaplasia without dysplasia, involving multiple sites

K31A19 Gastric intestinal metaplasia without dysplasia, unspecified site

K31A21 Gastric intestinal metaplasia with low grade dysplasia

K31A22 Gastric intestinal metaplasia with high grade dysplasia

K31A29 Gastric intestinal metaplasia with dysplasia, unspecified

L24A0 Irritant contact dermatitis due to friction or contact with body fluids, unspecified

L24A1 Irritant contact dermatitis due to saliva

L24A2 Irritant contact dermatitis due to fecal, urinary or dual incontinence

L24A9 Irritant contact dermatitis due friction or contact with other specified body fluids

L24B0 Irritant contact dermatitis related to unspecified stoma or fistula

L24B1 Irritant contact dermatitis related to digestive stoma or fistula

L24B2 Irritant contact dermatitis related to respiratory stoma or fistula

L24B3 Irritant contact dermatitis related to fecal or urinary stoma or fistula

M3110 Thrombotic microangiopathy, unspecified

M3111 Hematopoietic stem cell transplantation-associated thrombotic microangiopathy [HSCT-TMA]

M3119 Other thrombotic microangiopathy

M3505 Sjogren syndrome with inflammatory arthritis

M3506 Sjogren syndrome with peripheral nervous system involvement

M3507 Sjogren syndrome with central nervous system involvement

M3508 Sjogren syndrome with gastrointestinal involvement

M350A Sjogren syndrome with glomerular disease

M350B Sjogren syndrome with vasculitis

M350C Sjogren syndrome with dental involvement

M45A0 Non-radiographic axial spondyloarthritis of unspecified sites in spine

M45A1 Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region

M45A2 Non-radiographic axial spondyloarthritis of cervical region

M45A3 Non-radiographic axial spondyloarthritis of cervicothoracic region

M45A4 Non-radiographic axial spondyloarthritis of thoracic region

M45A5 Non-radiographic axial spondyloarthritis of thoracolumbar region

M45A6 Non-radiographic axial spondyloarthritis of lumbar region

M45A7 Non-radiographic axial spondyloarthritis of lumbosacral region

M45A8 Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region

M45AB Non-radiographic axial spondyloarthritis of multiple sites in spine

M5450 Low back pain, unspecified

M5451 Vertebrogenic low back pain

M5459 Other low back pain

P0082 Newborn affected by (positive) maternal group B streptococcus (GBS) colonization

P091 Abnormal findings on neonatal screening for inborn errors of metabolism

P092 Abnormal findings on neonatal screening for congenital endocrine disease

P093 Abnormal findings on neonatal screening for congenital hematologic disorders

P094 Abnormal findings on neonatal screening for cystic fibrosis

P095 Abnormal findings on neonatal screening for critical congenital heart disease

P096 Abnormal findings on neonatal screening for neonatal hearing loss

P098 Other abnormal findings on neonatal screening

P099 Abnormal findings on neonatal screening, unspecified

R051 Acute cough

R052 Sub acute cough

R053 Chronic cough

R054 Cough syncope

R058 Other specified cough

R059 Cough, unspecified

R3581 Nocturnal polyuria

R3589 Other polyuria

R4588 Non suicidal self-harm

R6330 Feeding difficulties, unspecified

R6331 Pediatric feeding disorder, acute

R6332 Pediatric feeding disorder, chronic

R6339 Other feeding difficulties

R7983 Abnormal findings of blood amino-acid level

S06A0XA Traumatic brain compression without herniation, initial encounter

S06A0XD Traumatic brain compression without herniation, subsequent encounter

S06A0XS Traumatic brain compression without herniation, sequela

S06A1XA Traumatic brain compression with herniation, initial encounter

S06A1XD Traumatic brain compression with herniation, subsequent encounter

S06A1XS Traumatic brain compression with herniation, sequela

T40711A Poisoning by cannabis, accidental (unintentional), initial encounter

T40711D Poisoning by cannabis, accidental (unintentional), subsequent encounter

T40711S Poisoning by cannabis, accidental (unintentional), sequela

T40712A Poisoning by cannabis, intentional self-harm, initial encounter

T40712D Poisoning by cannabis, intentional self-harm, subsequent encounter

T40712S Poisoning by cannabis, intentional self-harm, sequela

T40713A Poisoning by cannabis, assault, initial encounter

T40713D Poisoning by cannabis, assault, subsequent encounter

T40713S Poisoning by cannabis, assault, sequela

T40714A Poisoning by cannabis, undetermined, initial encounter

T40714D Poisoning by cannabis, undetermined, subsequent encounter

T40714S Poisoning by cannabis, undetermined, sequela

T40715A Adverse effect of cannabis, initial encounter

T40715D Adverse effect of cannabis, subsequent encounter

T40715S Adverse effect of cannabis, sequela

T40716A Underdosing of cannabis, initial encounter

T40716D Underdosing of cannabis, subsequent encounter

T40716S Underdosing of cannabis, sequela

T40721A Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter

T40721D Poisoning by synthetic cannabinoids, accidental (unintentional), subsequent encounter

T40721S Poisoning by synthetic cannabinoids, accidental (unintentional), sequela

T40722A Poisoning by synthetic cannabinoids, intentional self-harm, initial encounter

T40722D Poisoning by synthetic cannabinoids, intentional self-harm, subsequent encounter

T40722S Poisoning by synthetic cannabinoids, intentional self-harm, sequela

T40723A Poisoning by synthetic cannabinoids, assault, initial encounter

T40723D Poisoning by synthetic cannabinoids, assault, subsequent encounter

T40723S Poisoning by synthetic cannabinoids, assault, sequela

T40724A Poisoning by synthetic cannabinoids, undetermined, initial encounter

T40724D Poisoning by synthetic cannabinoids, undetermined, subsequent encounter

T40724S Poisoning by synthetic cannabinoids, undetermined, sequela

T40725A Adverse effect of synthetic cannabinoids, initial encounter

T40725D Adverse effect of synthetic cannabinoids, subsequent encounter

T40725S Adverse effect of synthetic cannabinoids, sequela

T40726A Underdosing of synthetic cannabinoids, initial encounter

T40726D Underdosing of synthetic cannabinoids, subsequent encounter

T40726S Underdosing of synthetic cannabinoids, sequela

T8082XA Complication of immune effector cellular therapy, initial encounter

T8082XD Complication of immune effector cellular therapy, subsequent encounter

T8082XS Complication of immune effector cellular therapy, sequela

U099 Post COVID-19 condition, unspecified

Y35899A Legal intervention involving other specified means, unspecified person injured, initial encounter

Y35899D Legal intervention involving other specified means, unspecified person injured, subsequent encounter

Y35899S Legal intervention involving other specified means, unspecified person injured, sequela

Z555 Less than a high school diploma

Z586 Inadequate drinking-water supply

Z5900 Homelessness unspecified

Z5901 Sheltered homelessness

Z5902 Unsheltered homelessness

Z5941 Food insecurity

Z5948 Other specified lack of adequate food

Z59811 Housing instability, housed, with risk of homelessness

Z59812 Housing instability, housed, homelessness in past 12 months

Z59819 Housing instability, housed unspecified

Z5989 Other problems related to housing and economic circumstances

Z7185 Encounter for immunization safety counseling

Z91014 Allergy to mammalian meats

Z9151 Personal history of suicidal behavior

Z9152 Personal history of non suicidal self-harm

Z92850 Personal history of Chimeric Antigen Receptor T-cell therapy

Z92858 Personal history of other cellular therapy

Z92859 Personal history of cellular therapy, unspecified

Z9286 Personal history of gene therapy

To check a summary of Codes

 

Return to check Deleted codes

Skilled Nursing Facility 3-Day Rule Billing

To qualify for Skilled Nursing Facility (SNF) extended care services coverage, Medicare patients must meet the 3-day rule before SNF admission. 

The 3-day rule requires,

• Three-day-consecutive inpatient hospital stay. 
• Three-day-consecutive stay counts inpatient setting.
• Starting with the calendar day of hospital admission.
• Doesn’t include the day of discharge or any pre-admission time spent in the ER or outpatient observation.

SNF extended care services are an extension of care a patient needs after a hospital discharge or within 30 days of their hospital stay (unless admitting them within 30 days is medically inappropriate).

Example

A 68-year-old male patient went to the hospital ER after falling on May 17th from his home and a physician admitted him to the hospital on the same day. On subsequently May 20, the hospital discharged him to SNF extended care services. 

For this case, the patient did qualify the 3-day rule. Hospitals can count the admission day (May 17th to May19th), but not the discharge day (May 20). 

Tips

Medicare considered inpatients meet the 3-day rule by staying 3 consecutive days in 1 or more hospital(s) as well.

See Inpatient Guidelines

New ICD codes for COVID-19

In March 2020 the Novel Coronavirus Disease, COVID-19, was declared a pandemic by the World Health Organization.

The Centers for Disease Control (CDC), under the National Emergencies Act Section 201 and 301, is announcing further additions to the ICD-10-CM Classification related to COVID-19, which will become effective January 1, 2021.

As a result of the ongoing COVID-19 public health emergency, the Centers for Disease Control and\ Prevention’s National Center for Health Statistics (CDC/NCHS) is implementing additional codes into ICD-10-CM for reporting to include,

• Encounter for screening for COVID-19  - Z11.52
• Contact with and (suspected) exposure to COVID-19 - Z20.822
• Personal history of COVID-19 - Z86.16
• Multisystem inflammatory syndrome (MIS) - M35.81
• Other specified systemic involvement of connective tissue - M35.89
• Pneumonia due to coronavirus disease 2019 - J12.82
• COVID-19 Positive - U07.1

These new codes will be effective January 1, 2021, to identify conditions resulting from COVID-19.

Check Related information

Cognitive Assessment Written Care Plan

A patient presents with cognitive impairment and or identified during the encounter then Medicare covers a separate visit for a cognitive assessment.

So, the provider can more thoroughly evaluate the patients for cognitive function and help with care planning.

Any clinician eligible to report evaluation and management services can offer this service, including physicians (MD and DO), nurse practitioners, clinical nurse specialists, and physician assistants.

The Cognitive Assessment & Care Plan Services (CPT code 99483) typically start with a 50-minute face-to-face visit that includes a detailed history and patient exam.

The physician can collect the information from the physical examination to create a written care plan.

The resulting written care plan includes initial plans to address as following,

• Neuropsychiatric symptoms
• Neurocognitive symptoms
• Functional limitations

The Patient and or caregiver referrals to community resources, as needed, with initial education and support.

Effective from January 1, 2021, Medicare increased payment for these services to $282 when provided in an office setting, added these services to the definition of primary care services in the Medicare Shared Savings Program, and permanently covers these services via telehealth.

Click here for Guidelines